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Bond University, Gold Coast, Australia and 5) Department of Primary Care Health Sciences, University of Oxford, Oxford, UKAbstractIn recent years there has been much debate and controversy surrounding the efﬁcacy and safety of neuraminidase inhibitors for inﬂuenza, in
part because the data underlying certain efﬁcacy claims were not available for independent scrutiny. In 2014, a Cochrane review was
published, based exclusively on an almost complete set of clinical study reports and other regulatory documents. Clinical study reports
can run to thousands of pages, providing an extensive amount of information on the planning, conduct and results of each trial. After a
protracted campaign to obtain the reports, the manufacturers of the medications provided them unconditionally. The review authors
subsequently published the underlying documents simultaneously with the Cochrane review, endorsing the concept of open science. In
the following commentary, the background to and results of this review are summarized and put into clinical context.
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published evidence onlyThe publically available evidence base for neuraminidase in-
hibitors has changed dramatically over the past 8 years. This
change has not come about through the results of new trials
being published in peer-reviewed journals. Rather, information
that was previously treated as conﬁdential, such as evidence
available only to regulators, became publically available. The
change was set in motion by a Japanese paediatrician who,
during the H1N1 outbreak of 2009, commented on the
Cochrane review of neuraminidase inhibitors for adults pub-
lished in 2006 [1]. Dr Keiji Hayashi questioned Cochrane’s
ﬁnding that oseltamivir reduces the risk of complications of
inﬂuenza, pointing out that this conclusion was based on aClinical Microbiology and Infection © 2014 European Society of Cmanufacturer-authored, pooled analysis of manufacturer-
sponsored randomized controlled trials, eight of which were
unpublished [2] (to this day the eight trials remain unpublished).
To address readers’ comments, authors of Cochrane reviews
are required to respond within 6 months, hence the neur-
aminidase inhibitors review authors set about obtaining the
unpublished data. Initially, they were unsuccessful [3] and the
data from the unpublished trials were not included in the
updated 2009 version of the review [4].The Cochrane review – 2009 to 2012: partial
clinical study reportsIn late 2009, the manufacturer of oseltamivir released part of
the clinical study reports (CSRs) for all ten trials. CSRs are
extensive documents reporting on clinical trials used to obtain
regulatory approval [5]. Roche (Basel, Switzerland) did this in
response to the 2009 Cochrane review of adults documenting
that the majority of oseltamivir data had never been published
and media reporting indicating that at least one major publishedClin Microbiol Infect 2015; 21: 217–221
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vided were still insufﬁcient to properly address Hayashi’s
comment. Further requests to the manufacturer were initially
not fruitful and the Cochrane researchers turned to the Eu-
ropean Medicines Agency (EMA), which introduced a policy of
sharing CSRs with third parties in late 2010. During the process
of obtaining oseltamivir CSRs from EMA, work on the 2012
version of the Cochrane review, which now included adults as
well as children [6], was ﬁnalized, hence that review was only
based on a subset of the relevant information (15 oseltamivir
and ten zanamivir studies). In addition, the EMA had in its
possession a full CSR for only one oseltamivir study. (EMA had
no data on zanamivir.)The Cochrane review – 2012 to 2014: full
clinical study reportsIn 2013, after a 4-year public campaign led by the BMJ
(bmj.com/tamiﬂu), Roche unconditionally released full CSRs for
all 77 sponsored clinical trials to the Cochrane group. The
manufacturer of zanamivir (GlaxoSmithKlein; Brentford, UK)
also provided a complete set of requested CSRs hence the 2014
version of the review [8] is based on the majority of relevant
information although Japanese and Chinese studies of oselta-
mivir (three trials in total) are not included because of lack of
complete CSRs.
The 2014 analysis included 46 randomized, placebo-
controlled trials (20 of oseltamivir and 26 of zanamivir) on
adults and children with conﬁrmed or suspected exposure to
naturally occurring inﬂuenza. Despite the title of the review
including the words ‘healthy adults’, the elderly and patients
with chronic diseases were included. The only population
excluded comprised immunocompromised patients. All treat-
ment trials recruited patients with inﬂuenza-like illness, deﬁnedFIG. 1. Time (in hours) to ﬁrst alleviation of symptoms in oseltamivir treatme
two under-recruited trials of patients with chronic obstructive airways disease
study report and similarly Study WV15819/WV15876/WV15978 includes t
manufacturer before reporting in the clinical study report. All other studies
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectas fever plus one constitutional symptom and one respiratory
symptom. Inﬂuenza status was determined post-randomization
using results from culture test and serology. Efﬁcacy analyses in
the Cochrane review were conducted on the intention-to-treat
population of all randomized patients with inﬂuenza-like-illness,
mimicking the situation of most clinicians in general practice,
and safety analysis was based on all patients receiving at least
one dose of study medication.
Results showed both oseltamivir and zanamivir have similar
effects in terms of efﬁcacy. Both medications reduce the time to
ﬁrst alleviation of symptoms of inﬂuenza-like illness in adults by
around 10%. The reduction for oseltamivir was 0.70 days (95%
CI −1.05 to −0.35 days, p <0.0001) whereas for zanamivir it
was 0.60 days (95% CI −0.81 to −0.39 days, p <0.00001). There
was no indication that the oseltamivir effect differed in sub-
groups of patients such as the elderly or those with chronic
obstructive airways disease. However, because trials on these
subgroups of patients were under enrolled, the manufacturer
chose to combine the three trials in the elderly in a single
clinical study report. The same occurred for the two trials in
patients with chronic obstructive airways disease (Fig. 1). There
was no evidence of a difference in treatment effect for zana-
mivir in the inﬂuenza-infected and non-inﬂuenza-infected sub-
groups (p = 0.53), suggesting that the effect of the
neuraminidase inhibitors is not speciﬁc to inﬂuenza (Fig. 2).
(Data were not available in a usable format to test this for
oseltamivir.)
In children, the evidence is based on a small number of trials.
For oseltamivir, time to ﬁrst alleviation of symptoms was
reduced in one trial of otherwise healthy children by 1.2 days
(95% CI −1.9 to −0.49 days, p = 0.001) but not in three trials of
children with asthma where patients in the oseltamivir groups
took 0.2 days longer for initial alleviation of symptoms (95% CI
–0.46 to 0.89 days, p = 0.53). There were only two trials of
zanamivir in children with insufﬁcient evidence of treatmentnt trials of adults. (Please note that Study WV15812/WV15872 includes
that were combined by the manufacturer before reporting in the clinical
hree under-recruited trials of the elderly that were combined by the
were in otherwise healthy adults.)
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 217–221
FIG. 2. Time (in days) to ﬁrst alleviation of symptoms in zanamivir treatment trials of adults by infection status.
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0.15 days, p = 0.08).
In terms of prevention of serious adverse outcomes there
was no evidence that oseltamivir reduced the risk of hospital-
ization (risk difference (RD) 0.15%, 95% CI −0.78 to 0.91) or
complications classiﬁed as serious or leading to study with-
drawal (RD 0.07%, 95% CI −0.78 to 0.44). There were incon-
sistent results for the outcome classiﬁed as ‘pneumonia’ across
the different drugs, age groups, and whether medication was
given for treatment or prophylaxis. Meta-regression showed
that the inconsistency was probably due to how the outcome
was assessed and recorded in the trials. In trials where pneu-
monia was reported as an adverse event there was evidence of
a treatment effect (relative risk (RR) 0.54, 95% CI 0.37–0.78)
but in trials where a more detailed diagnostic form including X-
ray conﬁrmation was used, there was no evidence of a treat-
ment effect (RR 1.0, 95% CI 0.70–1.45).
In prophylaxis trials, oseltamivir and zanamivir also showed
similar modest effects for efﬁcacy. They reduced the risk ofClinical Microbiology and Infection © 2014 European Society of Clinical Microbiologysymptomatic inﬂuenza in individuals (oseltamivir: RD 3.05%,
95% CI 1.83–3.88; zanamivir: RD 1.98%, 95% CI 0.98–2.54)
and in households (oseltamivir: RD 13.6%, 95% CI 9.52–15.47;
zanamivir: RD 14.84%, 95% CI 12.18–16.55) but there was no
evidence of an effect on asymptomatic inﬂuenza (oseltamivir:
RR 1.14, 95% CI 0.39–3.33; zanamivir: RR 0.97, 95% CI
0.76–1.24). Other prophylaxis efﬁcacy outcomes of the review
could not be assessed as planned. Inﬂuenza-like illness (not
diagnosed as inﬂuenza) was not deﬁned in the CSRs or fully
reported and prophylaxis trials were not designed to test the
effect of drug on interruption of person-to-person viral spread.
In exploratory analysis of the four prophylaxis trials of in-
dividuals using a deﬁnition for inﬂuenza-like illness of two or
more symptoms out of nasal congestion, headache, chills/
sweats, sore throat, cough, fatigue, myalgia and fever there was
no evidence that oseltamivir reduced risk of illness (RR 0.95,
95% CI 0.86–1.06). However, oseltamivir reduced the risk of
fever (RR 0.62, 95% CI 0.42–0.93) and reduced the probability
of testing positive for inﬂuenza (RR 0.59, 95% CI 0.41–0.85).and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 217–221
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shedding but does not reduce the risk of symptomatic illness.
Although outcomes were similar for efﬁcacy, they were not
in terms of harms. Nausea, vomiting, headache, psychiatric
syndromes, renal events and reduced antibody response to
inﬂuenza infection were all associated with oseltamivir in
various subgroups of trials whereas there was no evidence
suggesting that zanamivir is associated with an increased risk of
adverse events. However, a limitation of the zanamivir trials is
that the placebo contained lactose powder, which may have
masked a potential adverse effect of bronchospasm.
The clinical implications of these results are debatable. There
is insufﬁcient evidence that neuraminidase inhibitors reduce the
risk of rare but serious consequences of inﬂuenza such as
pneumonia and hospitalization. However, they appear to
reduce symptoms of inﬂuenza-like illness. The symptomatic
relief is not speciﬁc to inﬂuenza, is modest, and may be similar
to that of other cheaper over-the-counter medications such as
paracetamol, although this has never been assessed, despite
calls for this to happen during the recent inﬂuenza ‘pandemic’
[9]. Furthermore the more commonly prescribed oseltamivir is
associated with relatively common side effects (numbers
needed to harm around 20 to 30) such as nausea, vomiting and
headache. More worryingly, prophylaxis studies indicated that
oseltamivir is also associated with rarer but more serious
harms including psychiatric syndromes and renal adverse
events – and the reduction in antibody response could have
implications for future risk of infection.
The Cochrane review by Jefferson et al. [8] is novel in that it
is the ﬁrst to be based solely on an almost complete set of
clinical study reports (which were made publicly available on
the day of its publication) and other regulatory information.
Therefore reporting bias, a common limitation of systematic
reviews, has been greatly reduced. Furthermore, the review has
been conducted independently from the manufacturers of the
medications. A recent publication has shown that this distinc-
tion may be important [10]. However, a limitation is that all
included trials are industry sponsored, trials of which signiﬁ-
cantly overestimate results when compared with non-industry
trials [11,12], and another is that none were conducted in pa-
tients with severe inﬂuenza.
The complete set of clinical study reports can be down-
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